PsyBio Therapeutics

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company that develops novel formulations of psychoactive medications for mental health challenges and other disorders. Founded in 2020 by Evan Levine, Noah Davis, and Robert Nathan, the company is headquartered in Boca Raton, Florida. Levine, who serves as Chairman and CEO, brings over three decades of experience in biotechnology, drug development, and investment management to the company. His background includes leading and restructuring numerous public and private companies, demonstrating a track record in corporate leadership and generating investor returns.

The company's core business revolves around its proprietary platform technology for biosynthesizing psychedelic compounds. This technology, developed in collaboration with Miami University, uses genetically modified bacteria to produce tryptamines like psilocybin. This biosynthetic method is positioned as a more efficient alternative to chemical synthesis, which often involves toxic solvents and heavy metal catalysts. PsyBio's process is designed to be cheaper, faster, and more environmentally friendly, reportedly producing the active ingredient for a fraction of the cost of traditional methods. The company's business model is focused on drug development, with the goal of progressing its portfolio of compounds through regulatory protocols and human clinical trials to create new, psycho-targeted therapeutics.

PsyBio is developing a portfolio of both naturally occurring and new tryptamine-related compounds. Its research pipeline includes biosynthetic psilocybin (PB1818) for cancer-related depression, as well as other tryptamines and phenethylamines for neurological disorders. The company is not only working on compounds found in hallucinogenic mushrooms but is also exploring other plants and fungi to create optimized therapeutics. By leveraging a bio-medicinal chemistry approach, PsyBio uses known psychoactive compounds as templates to develop new precursors and analogs. The company has initiated the manufacturing of its compounds and is preparing for Investigational New Drug (IND) applications with the FDA, with an initial focus on studying its candidates in patients with cancer-related depression.

Keywords: PsyBio Therapeutics, biosynthetic psychedelics, psychoactive medications, mental health treatment, tryptamines, psilocybin, drug development, biotechnology, metabolic engineering, neurological disorders, Evan Levine, Miami University collaboration, genetically modified bacteria, psycho-targeted therapeutics, medicinal chemistry, clinical trials, pharmaceutical manufacturing, cancer-related depression, drug discovery platform, neuropharmacology